Plain-English translation of NCT06765850 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand the chemical signatures in blood and body fluids from melanoma patients at different stages of disease. By analyzing these samples using specialized laboratory techniques, they hope to find patterns that could help doctors detect melanoma earlier, catch it if it comes back, or spot when it has progressed to a more advanced stage.
Currently, doctors don't have reliable blood tests to catch melanoma early or predict recurrence. This study aims to find measurable chemical markers in the body that could eventually become simple, early-warning tests for melanoma patients.
You likely qualify if…
You likely don't qualify if…
If you join, you'll provide blood samples and possibly other tissue samples as part of your regular care at the clinic. These samples are stored in a research biobank and analyzed using specialized laboratory techniques. The study is ongoing, so you may be asked to provide samples at different points in your treatment or follow-up care.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
Germany
Enrollment target
~3,000 participants
Started
July 2022
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Frank Friedrich Gellrich, Dr. med.
Technische Universität Dresden
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.